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LETTERS TO THE EDITOR
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stick) with HCV-positive blood and of spouses of infected
people. Espinosa et al claim that a histological study [1]Mario Espinosa, Alejandro Marti´n-Malo, and Pedro Aljama
Co´rdoba, Spain showed that 9.5% of the anti-HCV positive patients on
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